Bristol-Myers Squibb Company /
RayzeBio, Inc.
Bristol-Myers Squibb completes acquisition of RayzeBio
What happened
Bristol-Myers Squibb Company completed its acquisition of RayzeBio, Inc. on Feb. 26, 2024. RayzeBio became a wholly owned subsidiary of Bristol-Myers Squibb Company.
The offer price was $62.50 per share in cash.
The source
Everything on this page comes from the source below.
Bristol-Myers Squibb completes acquisition of RayzeBio
This document is the source for the companies, stage, figure and people on this page.
Original filingUnlock with ProTimeline
Every date the source states, in order. Anything marked ahead is a target the source gives, not something that has happened.
Closed
The source this page is built from.
Source-verifiedPublished by the source
The source this page is built from.
Source-verified
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Request an inviteAlready invited? Sign in
Carrywatch Pro is by invitation. An invite lets you buy Pro.
By email · Weekly